We provide you with 20 years of free, institutional-grade data for OYST stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of OYST. Explore the full financial landscape of OYST stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about OYST stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Oyster Point Pharma, Inc(NASDAQ:OYST) 
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor ago...
Website: http://www.oysterpointrx.com
Founded: 2015
IPO Price: $16 (Oct 31, 2019)
Full Time Employees: 62 (May 2021)
CEO: Jeffrey A. Nau
Sector: Healthcare
Industry: Biotechnology